



24390-01-26-06.txt
SEQUENCE LISTING

<110> Yeda Research and Development Company Ltd.
<120> ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW PEPTIDE
<130> 1276302
<140> 09/647,457
<141> 2000-09-29
<150> PCT/IL99/00190
<151> 1999-09-29
<150> 123925
<151> 1998-04-02
<160> 15
<170> PatentIn version 3.3
<210> 1
<211> 28
<212> PRT
<213> Artificial Sequence
<220>
<223> being the immunologically active epitope
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa(1) is S or absent
<220>
<221> MISC_FEATURE
<222> (1)..(11)
<223> provided that when Xaa(11) is absent, Xaa(1) through Xaa(10), inclusive, are absent, and when Xaa(11) is D , Xaa(10) is A or absent
<220>
<221> MISC_FEATURE
<222> (1)..(10)
<223> when Xaa(10) is absent, Xaa(1) through Xaa(9), inclusive, are absent, and when Xaa(10) is A, Xaa(9) is I or absent
<220>
<221> MISC_FEATURE
<222> (1)..(9)
<223> when Xaa(9) is absent, Xaa(1) through Xaa(8), inclusive, are absent, and when Xaa(9) is I, Xaa(8) is F or absent
<220>
<221> MISC_FEATURE
<222> (1)..(8)
<223> when Xaa(8) is absent, Xaa(1) through Xaa(7), inclusive, are absent, and when Xaa(8) is F, Xaa(1) through Xaa(7) are, respectively, S, G, E, T, E, D, and T
<220>
<221> MISC_FEATURE

<222> (2)..(2)
 <223> Xaa(2) is G or absent

<220>
 <221> MISC_FEATURE
 <222> (3)..(3)
 <223> Xaa(3) is E or absent

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> Xaa(4) is T or absent

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> Xaa(5) is E or absent

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> Xaa(6) is D or absent

<220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> Xaa(7) is T or absent

<220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> Xaa(8) is F or absent

<220>
 <221> MISC_FEATURE
 <222> (9)..(9)
 <223> Xaa(9) is I or absent

<220>
 <221> MISC_FEATURE
 <222> (10)..(10)
 <223> Xaa(10) is A or absent

<220>
 <221> MISC_FEATURE
 <222> (19)..(19)
 <223> Xaa(19) is C, G, P

<220>
 <221> MISC_FEATURE
 <222> (25)..(25)
 <223> Xaa(25) is A, P

<220>
 <221> MISC_FEATURE
 <222> (25)..(28)
 <223> Xaa(28) is R or absent, provided that Xaa(25) and Xaa(26) are taken together to form a sequence selected from the group consisting of AP and PA

<220>
 <221> MISC_FEATURE
 <222> (26)..(26)

<223> Xaa(26) is P, A

<400> 1

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Val Val Gly Leu
1 5 10 15

Cys Thr Xaa Gln Ile Lys Thr Gly Xaa Xaa Cys Xaa
20 25

<210> 2

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> being the immunologically active epitope

<400> 2

Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
1 5 10 15

Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
20 25

<210> 3

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 3

Leu Val Val Gly Leu Cys Thr Cys Gln Ile Lys Thr Gly Pro Ala Cys
1 5 10 15

<210> 4

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 4

Ile Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly
1 5 10 15

Ala Pro Cys Arg
20

<210> 5
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 5

Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala
 1 5 10 15

Pro Cys Arg

<210> 6
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 6

Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
 1 5 10 15

Cys Arg

<210> 7
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 7

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys
 1 5 10 15

Arg

<210> 8
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 8

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
 1 5 10 15

Arg

<210> 9
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 9

Leu Val Val Gly Leu Cys Thr Pro Gln Ile Lys Thr Gly Pro Ala Cys
 1 5 10 15

Arg

<210> 10
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 10

Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
 1 5 10 15

Cys Thr Gly Gln
 20

<210> 11
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 11

Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
 1 5 10 15

<210> 12
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 12

Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
 1 5 10

<210> 13
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 13

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys
 1 5 10 15

<210> 14
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 14

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
 1 5 10 15

<210> 15
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 15

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
 1 5 10 15